Dianthus Therapeutics (DNTH) is a clinical-stage biotech company that develops antibody complement therapeutics. CEO Marino Garcia joins Oliver Renick to discuss DNTH. DNTH completed a merger with Magenta Therapeutics and began trading on the NASDAQ under the ticker “DNTH.” DNTH announced positive top-line phase 1 data for DNTH103 treatment. Tune in to find out more about the stock market today.
Morning Trade Live
15 Sep 2023
SHARE